High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): A high-affinity 5-HT2A receptor-selective agonist radioligand

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 11, 2008, Pages 6116-6123

  Nichols, David E ^a   Frescas, Stewart P ^a   Chemel, Benjamin R ^a   Rehder, Kenneth S ^b   Zhong, Desong ^b   Lewin, Anita H ^b  

^a PURDUE UNIVERSITY   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

5 HT2A receptor; Radioligand; Receptor binding

Indexed keywords

CINANSERIN; KETANSERIN; METHYL IODIDE; N (2 METHOXYBENZYL) 2,5 DIMETHOXY 4 IODOPHENETHYLAMINE; POTASSIUM CARBONATE; SEROTONIN 2A AGONIST; TRITIUM; VOLINANSERIN;

ARTICLE; BINDING AFFINITY; DEPROTECTION REACTION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; METHYLATION;

BINDING SITES; CELL LINE; CELL LINE, TUMOR; ETHYLAMINES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; IODINE RADIOISOTOPES; IODOBENZENES; KETANSERIN; NUCLEAR PROTEINS; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT2A; TRITIUM;

EID: 44449101636     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.04.050     Document Type: Article

References (20)

1. Burnet P.W., Eastwood S.L., Lacey K., and Harrison P.J. Brain Res. 676 (1995) 157-168
2. Willins D.L., Deutch A.Y., and Roth B.L. Synapse 27 (1997) 79-82
3. Hamada S., Senzaki K., Hamaguchi-Hamada K., Tabuchi K., Yamamoto H., Yamamoto T., Yoshikawa S., Okano H., and Okado N. Brain Res. Mol. Brain Res. 54 (1998) 199-211
4. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Babler A., Vogel H., and Hell D. Neuroreport 9 (1998) 3897-3902
5. Marek G.J., Wright R.A., Schoepp D.D., Monn J.A., and Aghajanian G.K. J. Pharmacol. Exp. Ther. 292 (2000) 76-87
6. Williams G.V., Rao S.G., and Goldman-Rakic P.S. J. Neurosci. 22 (2002) 2843-2854
7. Nichols D.E. Pharmacol. Ther. 101 (2004) 131-181
8. Nagatomo T., Rashid M., Abul M.H., and Komiyama T. Pharmacol. Ther. 104 (2004) 59-81
9. Cogolludo A., Moreno L., Lodi F., Frazziano G., Cobeno L., Tamargo J., and Perez-Vizcaino F. Circ. Res. 98 (2006) 931-938
10. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., Frank R.A., van Giersbergen P.L., McCloskey T.C., Johnson M.P., McCarty D.R., Poirot M., Senyah Y., Siegel B.W., and Widmaier C. J. Pharmacol. Exp. Ther. 277 (1996) 968-981
11. Johnson M.P., Hoffman A.J., Nichols D.E., and Mathis C.A. Neuropharmacology 26 (1987) 1803-1806
12. Glennon R.A., Seggel M.R., Soine W.H., Herrick-Davis K., Lyon R.A., and Titeler M. J. Med. Chem. 31 (1988) 5-7
13. Nelson D.L., Lucaites V.L., Wainscott D.B., and Glennon R.A. Naunyn-Schmiedeberg's Arch. Pharmacol. 359 (1999) 1-6
14. Braden M.R., Parrish J.C., Naylor J.C., and Nichols D.E. Mol. Pharmacol. 70 (2006) 1956-1964
15. Hofsløkken N.U., and Skattebøl L. Acta Chem. Scand. 53 (1999) 258-262
16. Van Veldhuizen J.J., Gillingham G.G., Garber S.B., Kataoka O., and Hoveyda A.H. J. Am. Chem. Soc. 125 (2003) 12502-12508
17. Kingsbury J.S., Harrity J.P.A., Bonitatebus Jr. P.J., and Hoveyda A.H. J. Am. Chem. Soc. 121 (1999) 791-799
18. Weyer U., Schafer R., Himmler A., Mayer S.K., Burger E., Czernilofsky A.P., and Stratowa C. Receptors Channels 1 (1993) 193-200
19. Parrish J.C., Braden M.R., Gundy E., and Nichols D.E. J. Neurochem. 95 (2005) 1575-1584
20. Chambers J.J., Parrish J.C., Jensen N.H., Kurrasch-Orbaugh D.M., Marona-Lewicka D., and Nichols D.E. J. Med. Chem. 46 (2003) 3526-3535